OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Therapy is 64. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Getting the host antiviral machinery back on track: Targeting viral suppressors of RNA interference	385
The ARDS microenvironment enhances MSC-induced repair via VEGF in experimental acute lung inflammation	280
α-L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: A phase 1/2 trial	252
Antitumor activity of a lectibody targeting cancer-associated high-mannose glycans	249
Modulation of NLRP3 inflammasomes activation contributes to improved survival and function of mesenchymal stromal cell spheroids	243
AAV vector manufacturing process design and scalability - Bending the trajectory to address vector-associated immunotoxicities	200
Engineering memory T cells as a platform for long-term enzyme replacement therapy in lysosomal storage disorders	186
Reduced-intensity conditioning in LV-mediated gene therapy for Fabry disease targeting HSPCs	170
Ablation of dysmorphic neurons is a safe and effective treatment for focal cortical dysplasia II	160
Response to: DNA transposon mechanisms and pathways of genotoxicity	159
Lipid nanoparticle-mediated silencing of osteogenic suppressor GNAS leads to osteogenic differentiation of mesenchymal stem cells in vivo	152
Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells	150
The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies	143
Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung damage upon aerosol delivery	143
From cortex to medulla: Navigating the thymic landscape of T cell education	136
Preclinical lentiviral hematopoietic stem cell gene therapy corrects Pompe disease-related muscle and neurological manifestations	136
Inhibition of NAD-GPx4 axis and MEK triggers ferroptosis to suppress pancreatic ductal adenocarcinoma	135
Reply to In vivo confusion over in vivo conversion	135
Biologics-based technologies for highly efficient and targeted RNA delivery	133
Targeting EBV gp42 for nasopharyngeal carcinoma prevention	125
Ad-justing macrophages for cancer immunotherapy	123
RNA interference targeting lipoprotein(a): A “big hit” against “little a”?	119
Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques	118
Targeting the central nervous system in lysosomal storage diseases: Strategies to deliver therapeutics across the blood-brain barrier	112
How to democratize cell and gene therapy: A global approach	111

Asparagine endopeptidase protects podocytes in adriamycin-induced nephropathy by regulating actin dynamics through cleaving transgelin	111
Exploiting viral infection/vaccination to focus high-affinity T cell populations into tumors using oncolytic viro-immunotherapy	107
Safety concern of recombination between self-amplifying mRNA vaccines and viruses is mitigated in vivo	105
RNAi mediated silencing of STAT3/PD-L1 in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors	103
CRISPR-Cas9n-mediated ELANE promoter editing for gene therapy of severe congenital neutropenia	103
Promotion or inhibition? This is a question in gene editing	100
An engineered mitoCBE facilitates efficient mitochondrial DNA editing and modified mitochondrial transfer	100
Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy	99
IL-1Ra gene transfer potentiates BMP2-mediated bone healing by redirecting osteogenesis toward endochondral ossification	93
Reversion of metabolic dysfunction-associated steatohepatitis by skeletal muscle-directed FGF21 gene therapy	92
Development of a peptide drug restoring AMPK and adipose tissue functionality in cancer cachexia	92
Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection	90
Recombinant neutralizing secretory IgA antibodies for preventing mucosal acquisition and transmission of SARS-CoV-2	88
Rescue of auditory function by a single administration of AAV-TMPRSS3 gene therapy in aged mice of human recessive deafness DFNB8	86
A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors	86
A novel regulatory mechanism network mediated by lncRNA TUG1 that induces the impairment of spiral artery remodeling in preeclampsia	86
miRNAs as neuro-oncologic therapeutics: A narrative review	85
CANT1 lncRNA Triggers Efficient Therapeutic Efficacy by Correcting Aberrant lncing Cascade in Malignant Uveal Melanoma	84
Recent progress and future challenges in structure-based protein-protein interaction prediction	84
MicroRNA-124-3p-enriched small extracellular vesicles as a therapeutic approach for Parkinson’s disease	84
High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury	84
Roles of lncRNAs in brain development and pathogenesis: Emerging therapeutic opportunities	82
Enhanced fatty acid oxidation via SCD1 downregulation fuels cardiac reprogramming	77
Low-inflammatory lipid nanoparticles facilitate safe mRNA vaccination against influenza virus infection	76
Molecular Therapy Family Highlights	75
Single-cell transcriptomics unveil a unique molecular profile of mesenchymal stem/stromal cell-induced myeloid-derived immune suppressor cells	74
Retraction Notice to: The YY1-HOTAIR-MMP2 Signaling Axis Controls Trophoblast Invasion at the Maternal-Fetal Interface	73
Targeting astrocytes with in vivo gene addition: Can it rescue loss of brain myelin?	73
Quo vadis American postdoc?	73
Response: Promise and open questions of optogenetic vision restoration by MCO	71
From bench to bloodstream: Lipid nanoparticles drive on-demand CAR-T cells	71
ANKRD22 promotes resolution of psoriasiform skin inflammation by antagonizing NIK-mediated IL-23 production	69
Viral platform engineering for targeted gene delivery to human hematopoietic stem cells	69
Autologous transplantation of mitochondria/rAAV IGF-I platforms in human osteoarthritic articular chondrocytes to treat osteoarthritis	68
Progress in skin gene therapy: From the inside and out	68
Late-Breaking Abstracts I	67
Long Noncoding RNA-Maternally Expressed Gene 3 Contributes to Hypoxic Pulmonary Hypertension	65
Superantigen-fused T cell engagers for tumor antigen-mediated robust T cell activation and tumor cell killing	64
Molecular Therapy’s growing influence	64